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Abstract
Cardiac pathology is emerging as a prominent systemic feature of spinal muscular atrophy 
(SMA), but little is known about the underlying molecular pathways. Using quantitative 
proteomics analysis, we demonstrate widespread molecular defects in heart tissue from the 
Taiwanese mouse model of severe SMA. We identify increased levels of lamin A/C as a 
robust molecular phenotype in the heart of SMA mice, and show that lamin A/C 
dysregulation is also apparent in SMA patient fibroblast cells and other tissues from SMA 
mice. Lamin A/C expression was regulated in-vitro by knockdown of the E1 ubiquitination 
factor UBA1, a key downstream mediator of SMN-dependent disease pathways, converging 
on β-catenin signalling. Increased levels of lamin A are known to increase the rigidity of 
nuclei, inevitably disrupting contractile activity in cardiomyocytes. The increased lamin A/C 
levels in the hearts of SMA mice therefore provide a likely mechanism explaining 
morphological and functional cardiac defects, leading to blood pooling. Therapeutic 
strategies directed at lamin A/C may therefore offer a new approach to target cardiac 
pathology in SMA.
Page 2 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Introduction
Spinal muscular atrophy (SMA) is a debilitating genetic disorder, traditionally classified as a 
neuromuscular disease due to the characteristic pathology of lower motor neuron 
degeneration and progressive muscle wasting (1). Accumulating evidence of pathology 
outside of the neuromuscular system, however, suggests that SMA should now be considered 
as a systemic condition (2). SMA has an incidence of approximately 1 in 10,000 live births 
(3), and in ~95% of patients it is caused by homozygous loss of SMN1 gene, resulting in 
insufficient levels of the ubiquitously expressed survival of motor neuron (SMN) protein (4). 
There is no cure for SMA, but the last few years have seen significant progress in the 
development of therapies aimed at alleviating symptoms by raising full-length SMN protein 
levels (5). Nusinersen (SpinrazaTM), an antisense oligonucleotide drug, is now widely 
available for children and young adults with SMA, and most recently, ZolgensmaTM 
(previously known as AVXS-101), an adeno-associated virus-based gene replacement 
therapy, was given approval by the FDA for the treatment of SMA children under 2 years 
of age. Though undoubtedly an enormous step forward, none of the strategies that have 
been developed so far show complete efficiency (5–8). Coupled with uncertainties around 
long-term effectiveness and extremely high price of both strategies, there is keen interest to 
find alternative therapeutic strategies that could, in combination with SMN-targeted therapy, 
offer maximum therapeutic benefit to all SMA patients (9). 
SMN perturbations influence organ development and function across multiple levels (2), and 
so it is likely that organ-specific and/or systemic therapy delivery may be necessary to fully 
rescue the SMA phenotype (5). For example, a systematic review of the literature in 2017 
found 58 studies that reported on a total of 264 SMA patients with cardiac abnormalities (10). 
A common finding among the 77 patients with the most severe type of SMA (Type I) was 
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structural pathology, observed mainly in the septum and/or cardiac outflow tract. All of the 
63 Type II SMA patients identified in the literature search had electrocardiogram (ECG) 
abnormalities, while the 124 patients with Type III SMA had cardiac rhythm disorders and/or 
structural abnormalities. In addition to the numerous reports of cardiac defects among SMA 
patients, the systematic review identified 14 studies that have documented cardiac pathology 
in mouse models of SMA (10). Common macroscopic findings include decreased heart size 
and decreased thickness of the left ventricular wall and interventricular septum, while a 
frequent microscopic observation was cardiac fibrosis, which was detected at a pre-
symptomatic stage of the disease in both severe and intermediate mouse models of SMA (10–
12). In addition, almost all studies of SMA mouse models reported bradyarrhythmias (10). A 
more recent study of a severe mouse model of SMA at pre- and early symptomatic time 
points confirmed many of these previous findings, but also noted significant pooling of blood 
in the heart, together with disorganization of cardiomyocytes and lack of trabecular 
compaction (13). These findings strongly resemble symptoms of cardiomyopathy (13), and 
indicate serious consequences for the normal electrical and mechanical functioning of the 
heart. 
A recent gene-expression study of hearts from the “Taiwanese” mouse model of severe SMA 
identified 205 genes that were down-regulated and 269 genes that were up-regulated at an 
early symptomatic time-point (i.e. P5) (14). Several of these changes were tracked back to a 
pre-symptomatic time-point, suggesting that cardiac defects might be attributable, at least in 
part, to cell autonomous mechanisms (14). To the best of our knowledge, this is the first 
study to date that has conducted a comprehensive analysis of molecular changes in the SMA 
mouse heart, and whilst it has generated novel insights about changes to the transcriptome, 
proteomic insights into the SMA heart are lacking. This is particularly important in the 
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context of emerging evidence showing that the SMN protein plays fundamental roles in 
protein translation (15, 16). In this study, we have conducted a comprehensive quantitative 
proteomics study of heart tissue from the Taiwanese mouse model of severe SMA and show 
that there is widespread dysregulation of protein expression in SMA compared to controls. 
We verified the robust increase of one of these proteins, lamin A/C, in the hearts of SMA 
mice, and propose a role for lamin A/C in SMA cardiac pathology, strongly supported by 
case reports of an adult form of SMA caused by mutations in the lamin A/C encoding gene, 
LMNA (17, 18). As with a wide range of neuromuscular conditions caused by mutations in 
LMNA, including Emery-Dreifuss muscular dystrophy, limb-girdle muscular dystrophy 1B, 
and dilated cardiomyopathy, cardiac involvement was a notable feature in each case of 
LMNA-associated SMA. A role for lamin A/C in SMA is strengthened further by experiments 
in which we demonstrate dysregulation across other cells and tissues, and a mechanistic link 
between lamin A/C and ubiquitin-like modifier activating enzyme 1 (UBA1) protein, a key 
contributor to SMN-dependent disease pathways (19–21).
Results
Quantitative proteomics analysis of heart tissue from severe SMA mice reveals 
widespread molecular defects
To determine the molecular consequences of SMN depletion in the heart of the Taiwanese 
mouse model of severe SMA (22), a quantitative comparison of the SMA and age-matched 
control heart proteome was undertaken using iTRAQTM mass spectrometry analysis. This 
approach identified 3105 proteins in total (Supplementary Table 1), of which 2479 were 
identified with a 5% local false-discovery rate. For reliable quantification, proteins identified 
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from just a single peptide were removed, after which, differentially expressed proteins were 
identified by removal of proteins with a fold-change of less than 1.25, and finally, exclusion 
of proteins with a p-value of >0.05 assigned to their fold changes. This left 383 proteins that 
met the specified criteria for differential expression, of which 177 proteins were increased 
and 206 were decreased in expression in SMA mouse heart compared to controls 
(Supplementary Table 2). Twenty-one of the differentially expressed proteins were also 
altered in expression at the gene level in a recent microarray study of hearts from SMA mice 
at an early symptomatic time-point (i.e. P5) (14), of which 16 followed the same direction of 
differential expression (Supplementary Table 3). 
Gene ontology (GO) analysis using the DAVID platform (23, 24) highlighted enriched 
biological processes and cellular components relating to the up- and down-regulated proteins, 
respectively (Supplementary Table 4). A relatively high proportion of up-regulated proteins 
were found to be blood-related (n=16), and although this compliments a previous report of 
blood pooling in the hearts of the Taiwanese SMA mouse model (13), these proteins were 
excluded from further analysis to retain focus on changes specific to the heart tissue. After 
also removing keratin-associated proteins (n=4), the remaining proteins were then subject to 
analysis using STRING 10 (25) to identify statistically significant associations between them. 
Comparison of the resulting networks with the GO analysis output (Supplementary Table 4) 
identified protein clusters associated with highly enriched molecular and/or biological 
processes. For the up-regulated proteins, enriched processes included organization and/or 
regulation of the cytoskeleton, cell junction, and extracellular matrix (Figure 1A), while 
clusters of down-regulated proteins were associated with translation and metabolic processes 
(Figure 1B).
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Lamin A/C expression is dysregulated in severe SMA mice and SMA patient fibroblasts
One of the 383 differentially expressed proteins, lamin A/C, was of particular interest to us 
since mutations in LMNA, the lamin A/C encoding gene, are known to cause an adult form of 
SMA (17, 18). Additionally, the analysis of published proteomic studies of the 
neuromuscular system in SMA (26) identified lamin A/C as a conserved molecular change 
across three separate studies of SMA (27–29). To date, however, these findings do not appear 
to have been verified, nor has lamin A/C been studied in the context of SMN-dependent 
pathways in heart. We therefore chose to verify and understand the individual contributions 
of lamins A and C to the overall lamin A/C expression trend, using quantitative western 
blotting of heart tissue extracts from P8 SMA mice and healthy littermate controls (see 
workflow in Figure 2A). This analysis confirmed a robust increase in lamin A (69%, p = 
0.0007) and C (91%, p = 0.0079) expression in SMA compared to control heart extracts 
(Figure 2B and 2C). Immunohistochemical analysis of SMA and control mouse heart sections 
revealed few lamin A/C positive cells in the ventricle lumen (Figure 2D), and although we 
cannot rule out a minor contribution, this result confirms that the increased lamin A/C levels 
cannot be solely attributed to circulating blood cells. Indeed, densitometry analysis of lamin 
A/C expression confirmed a robust upregulation of lamin A/C levels in the ventricle wall of 
SMA mouse heart sections compared to the unaffected controls (84%, p = 0.0002) (Figure 
2E). 
Protein extracts of SMA and control mouse brain, spinal cord, muscle, and liver tissue, as 
well as control and SMA patient dermal fibroblast extracts were analysed by quantitative 
western blotting to determine whether lamin A/C dysregulation extends beyond the heart. 
These analyses revealed widespread dysregulation of both lamin A and C, with differing 
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directions of expression change depending on the tissues examined (Figure 2B and 2C). A 
statistically significant reduction of lamin A levels was seen in the SMA patient fibroblast 
cells compared to those from healthy controls (84%, p = 0.0438), while a statistically 
significant upregulation of lamin A levels was found in the brain (25%, p = 0.0434) and liver 
(52%, p = 0.0026) tissue from SMA mice. Spinal cord extracts from SMA mice did not show 
a significant change in lamin A expression compared to the healthy controls, but they did 
show a significant increase in the levels of lamin C (43%, p = 0.0078), as did the liver (42%, 
p = 0.0075) and brain (43%, p= 0.0116). Patient fibroblast cells, on the contrary, showed no 
significant change in lamin C expression compared to the healthy controls, despite having a 
drastic reduction in lamin A levels. It was not possible to reliably determine whether lamin A 
or C were dysregulated in the skeletal muscle extracts due to large variability between 
samples, for reasons we are unable to explain. Lamin A dysregulation in SMA patient 
fibroblasts and SMA mouse heart (where protein levels were lowest, and highest, compared 
to controls, respectively) appears to occur post-transcriptionally, since RT-qPCR analysis 
showed no significant change in lamin A transcript levels in SMA compared to controls 
(Figure 2F).
Lamin A/C and UBA1 are mechanistically linked
Having established the widespread dysregulation of lamin A/C levels across SMA patient 
fibroblasts and mouse tissues (Figure 2), we next wanted to investigate whether there is a 
relationship between lamin A/C and UBA1. The justification for this is that a role for UBA1 
in SMN-dependent pathways has been well characterised across several models of SMA (19–
21), and previous research has shown that like UBA1 (19), lamin A/C is implicated in the 
regulation of the β-catenin signalling pathway (30, 31). In addition, a previous study reported 
decreased levels of UBA1 expression across a range of non-neuronal tissues from the 
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Taiwanese mouse model of SMA compared to controls, with the heart being most severely 
affected, followed by the liver (20). This is of particular interest in context with the current 
study, since heart tissue from SMA mice showed the greatest increase of lamin A/C levels 
across the tissues examined, also followed by the liver (Figure 2). (SMA patient fibroblasts 
appear to be an anomaly, as they were the only sample to show reduced lamin A levels 
compared to controls but had unchanged levels of UBA1 (Supplementary File, S4)). To 
investigate the relationship between lamin A/C, UBA1 and SMN, a western blot study of 
their relative protein expression levels was conducted using equal amounts of total protein 
from heart, muscle, liver, brain and spinal cord tissue extracts from healthy control mice and 
from healthy human fibroblasts. This revealed a strong inverse pattern of lamin A/C and 
UBA1 expression (Figure 3A) whereby the cells / tissues typically considered under the most 
mechanical strain (i.e. fibroblast cells, heart and muscle tissue) had high relative levels of 
lamin A/C and low relative levels of UBA1. Tissues under the least mechanical strain (i.e. 
liver, brain and spinal cord) showed the opposite pattern, with low relative levels of lamin 
A/C and high relative levels of UBA1 (Figure 3A). SMN followed the same expression trend 
as UBA1 across the tissues examined (Figure 3A). 
Having established an inverse correlation between UBA1 and lamin A/C expression across a 
range of tissues, we next wanted to determine whether a mechanistic link exists between 
them. Knockdown of UBA1 expression in human embryonic kidney (HEK) cells resulted in a 
~43% upregulation of lamin A expression (p = 0.0398), independent of changes to lamin C 
and SMN (Figure 3B). We also examined mouse embryonic fibroblast cells lacking the 
LMNA gene (32), and found that UBA1 (55%, p = 0.0053) and SMN (21%, p = 0.0016) were 
significantly reduced compared to the control (Figure 3C). Immunostaining of control and 
SMA patient fibroblasts showed colocalisation between UBA1 and lamin A at the nuclear 
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periphery in control and SMA cells (Figure 4A), indicating a possible interaction between 
lamin A/C and UBA1. To investigate this further, an immunoprecipitation from control and 
SMA mouse heart extracts was performed using a lamin A/C monoclonal antibody attached 
to magnetic beads. Although both lamin A/C and UBA1 were easily detected in SMA and 
control heart extracts by western blot analysis, UBA1 was undetectable in the eluates 
following pull-down (Figure 4B). It is important to note though that an interaction between 
lamin A/C and UBA1 cannot be ruled out on this basis since physiological interactions may 
occur between a minor proportion of the total protein present and/or it may be vulnerable to 
disruption by protein extraction methods (33). Interestingly, however, we did find that a small 
proportion of the total β-catenin co-immunoprecipitated with lamin A/C from both SMA and 
control heart extracts, providing evidence that lamin A/C interacts with β-catenin in the heart 
under normal physiological conditions (Figure 4B). When taken together, these experiments 
demonstrate a mechanistic link between lamin A/C and UBA1, a proven contributor to SMN-
dependent disease pathways, and highlight β-catenin signalling as a potential pathway upon 
which they both converge. 
Discussion
A small percentage of SMA cases are associated with mutations in genes other than SMN, 
including UBA1 (34), GARS1 (35) and LMNA (17, 18). Mutations in the UBA1 gene, which 
encodes the UBA1 protein, cause a form of X-linked infantile SMA (SMAX2) (34), and a 
role for UBA1 in SMN-dependent pathways has also been well characterised across several 
models of SMA (19–21). Mutations in GARS1 are known to cause infantile (36, 37) as well 
as an adult onset type of SMA (35). Dysregulation of UBA1/GARS1 pathways disrupted 
sensory neuron fate and altered sensory-motor connectivity in SMA mice, both of which were 
Page 10 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
corrected following restoration of UBA1 levels (21). Unlike UBA1 and GARS1, however, the 
involvement of LMNA in SMN-dependent disease pathways has so far been unexplored. 
Here, we demonstrated that there are widespread molecular defects in heart tissue from the 
Taiwanese mouse model of severe SMA, one of which is the protein product of the LMNA 
gene, lamin A/C. We verified the robust increase of lamin A/C in the hearts from SMA mice, 
and have identified a mechanistic link between UBA1 and lamin A/C. 
The A-type lamins, lamin A and C, are encoded by LMNA gene, and in addition to providing 
structural support to the nucleus, are involved in several other functions including 
mechanosignaling, chromatin organization and regulation of gene expression (38). Mutations 
in LMNA gene cause a spectrum of disorders known as laminopathies, the majority of which 
prominently feature cardiac pathology. The adult form of SMA caused by LMNA mutations is 
no exception to this, as each of the patients described experienced cardiac problems with 
disease progression and required a pacemaker. Examination of family history in each case 
also revealed a high frequency of cardiac abnormalities and sudden unexplained cardiac 
deaths (15, 16). This indisputable link between lamin A/C mutations and cardiac pathology in 
a wide range of conditions, including a rare form of SMA, leaves very little doubt that correct 
functioning of lamin A/C is a key requirement for the maintenance of cardiac health. The 
finding here that lamin A/C is robustly increased in heart tissue from a mouse model of SMA 
therefore strongly suggests that lamin A/C is responsible, at least in part, for previously 
reported cardiac defects in SMA. 
Lamin A/C plays a significant role in the regulation of cell stability and cell dynamics (39), 
and its expression levels correlate with tissue stiffness, where rigid tissues have the highest 
levels and softer tissues the least (40). This therefore suggests that changes in lamin A/C 
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expression may be most pathologically relevant in SMA in highly mechanically active tissues 
such as the heart, where increased expression of lamin A/C is likely to impair its proper 
functioning. Indeed, increased rigidity of human and rat cardiomyocytes increased the extent 
to which cells/tissues resist deformation (i.e. passive tension) in-vitro (41, 42), and in-vivo rat 
experiments showed that higher passive tension slows the dynamics of myocardium 
contractions and induces functional heart defects (42). Increased cardiomyocyte rigidity was 
also identified in a cell model carrying a mutation in the LMNA gene (43). This mutation 
causes severe dilated cardiomyopathy in humans (43), which strongly mirrors the phenotype 
previously observed in severe and mild mouse models of SMA, including thinning of 
ventricle walls and interventricular septum (11, 13), and dilation of ventricles (13, 44, 45). 
The pathological end-point of dilated cardiomyopathy is systolic heart failure where the heart 
cannot pump blood properly. This would be evidenced by decreased ejection fraction and 
blood pooling in ventricles; both of which were identified in SMA mice (13, 44–46) and 
SMA patients (18, 47, 48). In the context of SMN-dependent SMA, it seems highly likely, 
therefore, that increased levels of lamin A/C would lead to stiffening of the cardiomyocytes, 
impeding their ability to contract properly and inducing the cardiac defects previously 
reported in SMA. In addition, cardiac fibrosis has been described in patients harbouring a 
LMNA mutation (49, 50), and was frequently reported in SMA patients and mouse models of 
SMA (10), even at a pre-symptomatic stage of the disease in both severe and intermediate 
mouse models of SMA (11, 12). As cardiac fibrosis is a key regulator of myocardial rigidity 
(42), it is therefore possible that this might further exacerbate problems described above 
(Figure 5).
A role for lamin A/C in SMA is strengthened further by our data demonstrating a mechanistic 
link between lamin A/C and UBA1, a key contributor to SMN-dependent disease pathways 
Page 12 of 42Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
(19–21). It seems highly likely that this mechanism converges on the β-catenin signalling 
pathway, since both lamin A/C and UBA1 are implicated in its regulation (19, 30, 31). UBA1 
controls the stability of β-catenin through the canonical ubiquitin-proteasome pathway, and 
deficiency in UBA1 protein levels leads to β-catenin accumulation and neuromuscular 
pathology in SMA (19). Defective Wnt/β-catenin signalling was found to contribute to the 
pathology of dilated cardiomyopathy caused by mutation in LMNA gene (30), and in a 
separate study, lamin A/C was shown to regulate the differentiation fate of mesenchymal 
stem cells (MSCs) by controlling dynamics of the Wnt/β-catenin signalling pathway (31). 
Lamin A/C overexpression, for example, increased nuclear levels of β-catenin and activated 
the Wnt signalling pathway to promote osteoblast differentiation (31). The same study also 
provided evidence of an interaction between lamin A/C and β-catenin by 
immunoprecipitation of nuclear proteins from MSCs forcibly overexpressing lamin A/C (31). 
This physical interaction was proposed as a mechanism by which β-catenin is translocated to 
the nucleus (31). Here, we further expanded the knowledge of the relationship between lamin 
A/C and β-catenin, by demonstrating an interaction between them in heart extracts under 
normal physiological conditions.
The arguments above support the hypothesis that lamin A/C dysregulation is likely to be 
responsible, at least in part, for previously reported cardiac defects in SMA, but other 
proteins identified in this screen also offer insight into the molecular defects underlying 
cardiac abnormalities in SMA. For example, two such proteins, SUN domain-containing 
protein 2 (SUN2) (51) and cell division cycle 5-like protein (Cdc5l) (52), are known lamin 
A/C interactors and may provide further insights into lamin A/C-associated pathways in 
SMA. Like LMNA, mutations in SUN2, the gene encoding the SUN2 protein, have been 
associated with Emery-Dreifuss muscular dystrophy, a neuromuscular disorder often 
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associated with cardiac defects (53). Cdc5l, on the other hand, is a known splicing complex 
component that appears to require lamin A/C in order to regulate its assembly and targeting 
to the spliceosomal complex (52). Alterations to this interaction may therefore affect splicing 
and gene transcription, further exacerbating the downstream molecular consequences of 
reduced SMN expression. With this in mind, it is interesting to note that a large proportion of 
the down-regulated proteins in the SMA mouse heart were associated with translation, and re-
enforces previous work showing that the SMN protein plays fundamental roles in protein 
translation (15, 16). It is also highly relevant that we found a large proportion of the down-
regulated proteins in the SMA heart to be associated with metabolic processes, while the up-
regulated proteins were strongly associated with cytoskeletal and extracellular matrix 
organisation (Figure 1). Imbalances in contractile performance are known to promote 
remodelling and dedifferentiation of adult cardiomyocytes; the consequences of which 
include cytoskeletal rearrangement, restructuring of contractile apparatus, and reduced 
oxidative metabolism (54). Ironically, it seems that these adaptive processes - presumably 
intended to protect the cardiomyocytes in times of mechanical and/or molecular stress – can 
lead to adverse consequences for the heart (54). Disruption of actin cytoskeleton, for 
example, can impair contractile properties of cardiomyocytes and was implicated in initiation 
of cardiomyocyte apoptosis (55). 
Here we have offered new insight into the molecular defects underlying cardiac abnormalities 
in SMA, but other important questions remain that are worthy of further attention. It would 
be of interest in the future, for example, to explore the functional consequences of lamin A/C 
dysregulation in other cells and tissues throughout the natural history of disease progression 
in SMA. Moreover, identification of upstream regulators of lamin A/C may help to unravel 
the tissue-specific regulatory mechanisms that act on lamin A/C in response to SMN 
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depletion. Finally, and most importantly, it will be crucial to determine the extent to which 
SMN-replacement therapies reverse the molecular defects in SMA, and whether this is 
sufficient to fully rescue the cardiac defects widely reported across SMA patients and mouse 
models. When doing so, it would be important to monitor cardiac health longitudinally to 
determine whether new phenotypes emerge following long-term SMN-replacement therapy, 
and with increasing age. Therapies primarily designed to target neuronal tissues, such as 
Nusinersen, are especially relevant in this context since they are unlikely to rescue 
pathological defects in SMA heart. This knowledge, together with a broader understanding of 
the interplay between lamin A/C and other regulators of heart function in SMA, would help 
to isolate the most appropriate targets for therapy design that could, in combination with 
SMN-targeted therapy, offer maximum therapeutic benefit to all SMA patients.
Materials and Methods
Spinal muscular atrophy mouse model
The Taiwanese mouse model (original strain purchased from Jackson Laboratories, No. 
005058), heterozygous for the SMN2 transgene on Smn null background (Smn−/−;SMN2tg/+) 
(22) and age-matched phenotypically normal controls (Smn+/-; SMN2tg/o) were maintained in 
SPF facilities at the University of Edinburgh. The breeding strategy, and genotyping using 
standard PCR protocols, were employed as previously described (56). Tissue was harvested 
at a symptomatic time point, postnatal day 8 (P8). All animal work was carried under the 
appropriate Project and Personal Licenses from the UK Home Office (PPL:60/4569) and 
following local ethical review.
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Quantitative proteomics analysis
Total protein extracts were prepared from the hearts of postnatal day 8 (P8) SMA mice (n = 
5) and healthy littermate mice (n = 5) for iTRAQ quantitative mass spectrometry analysis as 
previously described (57). Following trypsin digestion, peptides were labelled with iTRAQTM 
tagging reagents according to the protocol in the iTRAQ kit and were assigned to each 
sample group as follows: 114-control and 115-SMA.
High pH reverse-phase liquid chromatography (RPLC) fractionation
All iTRAQ labelled peptides were combined into one tube, concentrated using a vacuum 
concentrator (ThermoSavant, ThermoFisher Scientific) and resuspended in 100 µl of buffer A 
(10 mM ammonium formate (NH4HCO2), 2 % acetonitrile (MeCN), pH 10.0). The peptides 
were then fractionated by high pH reverse-phase liquid chromatography (RPLC) using a C18 
column (XBridge C18 5 µm, 4.6 x 100 mm, Waters). The column was rinsed with 96 % 
buffer A at 1 mL/min for 6 minutes until the optical density (OD) on the ultraviolet 
chromatogram returned to the baseline. The gradient ran from 4-28 % of buffer B (10 mM 
NH4HCO2, 90 % MeCN, pH 10.0) for 30 minutes to 28-50 % buffer B for 6 minutes. The 
column was rinsed in 80 % buffer B for 5 minutes and then was re-equilibrated at initial 
conditions with 4 % buffer B for 11 minutes. Fractions of 0.5 mL were collected every 30 
seconds. The UV chromatogram was analysed and the fractions with similar peptide 
concentration across the elution profile were combined to give 12 fractions. The pooled 
fractions were concentrated in a vacuum concentrator and resuspended in 30 µl of 0.1 % 
formic acid (FA). 
Liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) analysis
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One third of each fraction containing the labelled peptides was analysed by mass 
spectrometry. Peptides were separated by liquid chromatography (LC) using a nanoLC Ultra 
2D plus loading pump and nanoLC AS-2 autosampler chromatography system (Eksigent). 
Peptides were loaded with buffer A (2% MeCN, 0.05% TFA in ultrapure water) and bound to 
an Acclaim PepMap100 trap (100 µm x 2 cm) (ThermoFisher Scientific). The trap was then 
washed for 10 minutes with buffer A, after which the trap was turned in-line with the 
analytical column (Acclaim PepMap RSLC column, 75 µm x 15 cm). The analytical solvent 
system consisted of buffer A and buffer B (98 % MeCN, 0.1 % FA in ultrapure water) at 300 
nl/min flow rate. Peptides were eluted using the followed gradient: linear 2-20 % of buffer B 
over 90 minutes, linear 20-40 % of buffer B for 30 minutes, linear 40-98% of buffer B for 10 
minutes, isocratic 98% of buffer B for 5 minutes, linear 98-2% of buffer B for 2.5 minutes 
and isocratic 2% buffer B for 12.5 minutes. The eluent was sprayed with a NANOSpray II 
source (electrospray ionization, ESI) into the TripleTOF 5600+ tandem mass spectrometer 
(AB Sciex), controlled by Analyst® TF software (AB Sciex). The mass spectrometer was 
operated in data-dependent acquisition (DDA) top20 positive ion mode with 120 ms 
acquisition time for MS (m/z 400-1250) and 80ms for MS/MS (m/z 95-1800), and 15 seconds 
of dynamic exclusion. MS/MS was conducted with a rolling collision energy (CE) inclusive 
of present iTRAQ CE adjustments.
The twelve raw mass spectrometry data files were analysed by ProteinPilot software, version 
5.0.1.0 (Applied Biosystems) with the ParagonTM database search and Pro GroupTM 
Algorithm using the UniProtKB/Swiss-Prot FASTA database. The general Paragon search 
analysis parameters were: type ‘iTRAQ4plex (Peptide Labeled)’, cysteine alkylation 
‘MMTS’, digestion ‘trypsin’ as the cleavage enzyme, instrument ‘TripleTOF, and species 
‘Mouse’ for sample parameters; processing parameters were specified as ‘quantitative’, ‘bias 
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correction’, ‘background correction’; ‘thorough ID’ and ‘biological modifications’. Proteins 
that showed a Protein Threshold > 5 were used for the Pro Group Algorithm to calculate the 
relative quantification of the protein expression, generating an error factor and p-value. A 
false discovery rate (FDR) analysis was performed using the Proteomics System Performance 
Evaluation Pipeline (PSPEP). 
Bioinformatics analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID 6.8) (23, 24) 
was used for the gene ontology (GO) analysis. The analysis was performed separately for 
upregulated and downregulated proteins, and included terms with at least two annotated 
proteins and p-value ≤ 0.05. Differentially expressed proteins were also analysed using the 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 10 (25) to identify 
statistically significant interactions between them. Association network analysis was 
performed with high confidence (0.700) interaction score for upregulated and with highest 
confidence (0.900) interaction score for downregulated proteins to exclude false positive 
results. 
Cell culture 
Skin fibroblast cells from the Coriell Cell Repository (Supplementary File, S1) were grown in 
high glucose Dulbecco's Modified Eagle Medium (DMEM; Gibco) with 10% fetal bovine 
serum (FBS; Gibco) supplemented with 1% non-essential amino acids (MEM-NEAA; Gibco) 
and 1 % penicillin-streptomycin (PEN-STREP; Lonza). Wild type and LMNA knockout 
mouse embryonic fibroblast cells (MEFs) (32) were grown in DMEM (Gibco) with 15% FBS 
(Gibco) supplemented with 1% MEM-NEAA (Gibco) and 1 % PEN-STREP (Lonza). 
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HEK293 cells were obtained from European Collection of Authenticated Cell Cultures. Cell 
culture and knockdown of ubiquitin-like modifier-activating enzyme 1 (UBA1) was 
performed as previously described (21). Briefly, HEK293 cells were grown in DMEM (Life 
Technologies) with 10% FBS (Sigma), penicillin/streptavidin (Invitrogen) and L-glutamine 
(Invitrogen). Cells were transfected with RNAiMax (Invitrogen) and 2.5µM Silencer Select 
Validated UBA1 siRNA (s601, targeted against exons 24 and 25; Life Technologies) or 
2.5µM negative control siRNA 2 (Life Technologies) according to the manufacturer’s 
instructions. Control (CTR) and UBA1 knockdown (UBA1 KD) HEK cells were harvested 
48h after transfection.
Western blotting
Protein extraction, SDS-PAGE and western blotting were performed as previously described 
(58). Briefly, after SDS-PAGE a part of the gel was excised and stained with Coomassie blue 
as an internal loading control for total protein. Proteins from the remaining part of the gel 
were transferred to nitrocellulose membrane by western blotting overnight. Membranes were 
blocked with 4% powdered milk and incubated with primary antibodies in dilution buffer 
(1% FBS, 1% horse serum, 0.1% BSA in PBS with 0.05% Triton X-100) for a maximum of 
two hours. Primary antibodies were as follows: mouse anti-SMN (MANSMA12 2E6 (59); 
1:100), rabbit anti-UBA1 (Novus; NBP2-67816; 1:500-1:1000), mouse anti-lamin AC 
(MANLAC1 4A7 (60); 1:100) was used for cell extracts and rabbit anti-lamin AC (Abcam; 
ab169532; 1:2000) was used for tissue extracts. Following incubation with HRP-labelled 
rabbit anti-mouse Ig (DAKO, P0260) or HRP-labelled goat anti-rabbit Ig (DAKO, P0488) in 
dilution buffer at 0.25 ng/mL, membranes were incubated with West Pico or West Femto 
(Thermo Fisher) and visualised using a Gel Image Documentation system (Biorad). 
Densitometry measurements of antibody reactive bands were obtained using Fiji software 
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(v1.51) (61) and were normalised to densitometry measurements of the Coomassie stained 
gel. For densitometry measurements only, contrast and brightness were adjusted uniformly 
across the gel and blot to decrease the background and enhance signal detection.
RT-qPCR
Total RNA was extracted using RNeasy Plus Mini kit (Qiagen) and quantified with a 
NanoDrop ND- 1000 spectrophotometer (Thermo Fisher). Absorption ratios (OD260/OD280 
nm; OD260/OD230 nm) were used to verify the integrity of the RNA. Total RNA was reverse 
transcribed using SuperScrip VILO cDNA Synthesis Kit (Invitrogen). Quantitative PCR was 
performed in QuantStudio 3 Real Time PCR system (Applied Biosystems), using SYBR 
Green detection system (SYBR Select Master Mix; Applied Biosystems). All PCR reactions 
were performed in triplicates and contained 3.75 ng of cDNA (fibroblast cells) or 2.8 ng of 
cDNA (heart tissue), and 300 nM Forward and 300 nM Reverse primers in the final volume 
of 20 μL. Parallel wells with no cDNA (NTC; no-template controls) were run for each gene 
to control for contamination. RNA Polymerase II Subunit J (POLR2J) and TATA-Box 
binding protein (TBP) were used as reference genes as they have previously demonstrated 
stable expression across tissues (62). Relative gene expression was quantified using Pfaffl 
method (63). The parameters of the reactions were 50°C for 2 min, 95°C for 10 min, and 40 
cycles of 95°C for 15 sec and 60°C for 1 min. Dissociation curves were obtained for each 
sample and PCR products were run on 1% agarose gel for a quality control. Primer sequences 
for lamin A, POLR2J and TBP are available in the Supplementary File (S2). Efficiency of the 
primer pairs was determined by making serial dilutions of the cDNA, plotting the log values 
of the cDNA against the Ct (cycle threshold) values, and using a slope to calculate the 
efficiency according to the equation: E = 10[–1/slope] x 100 (63).
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Immunohistochemistry (IHC)
SMA and control mouse hearts were fixed in 4% paraformaldehyde for 4 hours, 
cryopreserved in 30% sucrose solution with 0.1% sodium azide and subsequently embedded 
in a 1:1 solution of 30% sucrose and optimum cutting temperature compound (OCT) at -
40oC. Ventricular heart sections (7µm) were air dried for 1 hour and subjected to antigen 
retrieval by submersion for 20 minutes in 10mM sodium citrate buffer at 90°C, followed by 
30 minutes cooling remaining in solution. Sections were incubated for 2 hours in blocking 
solution (0.4% bovine serum albumin (BSA), 1% Triton X-100 in 0.1M PBS) at 4°C and then 
overnight with rabbit anti-lamin A/C antibody (Novus; NBP2-19324) at 4°C. Slides were 
washed twice (10 minutes each in PBT (0.1M phosphate buffered saline (PBS) with 0.1% 
Tween-20)), followed by one 10 minute wash in 0.1M PBS. Sections were incubated with 
Cy3 goat anti-rabbit IgG (H+L) (ThermoFisher; A10520) for 2 hours at 4°C, with successive 
washes as before. Sections were mounted using MOWIOL media (10% Mowiol (Sigma; 
81381), 20% glycerol, 50% 0.2M Tris buffer pH 8.5, 3% 1,4-diazobicyclooctance made up in 
distilled water) containing 4’,6-diamidino-2-phenylindole (DAPI). 
For the Figure, sections were imaged using Nikon eclipse e400 microscope (20x objective). 
For the purpose of quantification, sections were imaged using a Zeiss LSM710 inverted 
confocal microscope (63x objective). Densitometry measurements of lamin A/C staining in 
the heart ventricles were performed using Fiji software (version 1.51) (61). Images were 
calibrated to optical density (OD) as previously described (58), and rectangular selection tool 
of fixed size was used to measure OD of the ventricle wall. Prior to statistical analysis, the 
OD of the background was subtracted from the OD measurements of the ventricle wall. Nine 
sections from each mouse were used in the analysis.
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Immunocytochemistry
Fibroblast cells were fixed in acetone: methanol solution (50:50) for 10 minutes, washed with 
PBS three times for five minutes and incubated with rabbit anti-UBA1 (Novus; NBP2-67816; 
1:100) and mouse anti-lamin A (Santa Cruz; sc-71481; 1:50) in blocking buffer (1% FBS and 
1% HS in PBS) for one or two hours. After incubation with goat anti-rabbit IgG Alexa Fluor 
488 and anti-mouse IgG Alexa Fluor 546 (Life Technologies; 5 μg/mL) in blocking buffer for 
one hour, cells were stained with DAPI (Sigma; 0.4 μg/mL) for 10 minutes and mounted 
using Hydromount (National diagnostics). Between each step cells were washed with PBS 
three times for five minutes. Images were obtained using Leica SP5 confocal microscope 
with 63× oil immersion objective. 
Immunoprecipitation 
Immunoprecipitation was performed as described previously (64). Briefly, anti-mouse Pan 
Ig-coated magnetic beads (50μl) (Dynal, Oslo) were washed with 4% BSA in PBS, then 
incubated with an anti-lamin A/C monoclonal antibody (26) (neat, 50μl) for 1 hour at room 
temperature with gentle rolling. The beads were then washed and incubated for 1 hour at 
room temperature with RIPA extracts of heart tissue from SMA and healthy littermate control 
mice (15μl) on a roller. The beads were washed thoroughly with RIPA buffer before eluting 
captured material by heating at 900C for 3 minutes in 1 x SDS sample buffer (30μl) (2% 
sodium dodecyl sulphate- SDS, 10% glycerol, 5% 2-mercaptoethanol, 62.5 mM Tris-HCl, pH 
6.8). Samples were subjected to western blotting as described above. Primary antibodies were 
as follows: rabbit anti-lamin AC (Abcam; ab169532; 1:2000), rabbit anti-UBA1 (Novus; 
NBP2-67816; 1:1000) and mouse anti-β-catenin (BD Transduction Laboratories; 610154; 
1:1000).
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Statistical analysis
All statistical analyses were performed in GraphPad Prism version 8.0.1 for Windows, 
GraphPad Software, San Diego, California USA, www.graphpad.com. The Shapiro-Wilk test 
was first used to assess the distribution of the data, followed by unpaired two-tailed t-test for 
parametric data, and a Mann-Whitney U test for a non-parametric data. All data are presented 
as mean +SD. Statistical significance was considered to be p ≤ 0.05 for all analyses.
Supplementary material
Supplementary Material is available at... 
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Figure legends
Figure 1. Bioinformatics analysis of the proteins dysregulated in heart tissue from SMA 
mice. A) Upregulated proteins (n=177) and B) downregulated proteins (n=206) were 
subjected to STRING 10 analysis. Of these, 103 upregulated and 91 downregulated proteins 
are not shown as statistically significant interactions were not identified in STRING 10. 
Protein associations were identified with high confidence (0.700) interaction score for A) 
upregulated and with the highest confidence (0.900) interaction score for B) downregulated 
proteins. The thickness and colour of the lines indicate confidence of the interaction (see 
legend inset in figure). Protein networks were compared to the GO analysis output 
(Supplementary Table 4). The analysis identified protein clusters that associate with enriched 
GO terms in the cellular component (black) and biological process (red) domain. Proteins 
annotated to each term are shown in corresponding circles.  
Figure 2. Widespread dysregulation of lamin A/C expression in fibroblasts from SMA 
patients and in tissues from SMA mice (P8) A) Schematic diagram showing the 
quantitative western blot analysis workflow. Total protein extracts from human fibroblast 
cells and mouse tissues were subjected to SDS-PAGE. A part of the gel was stained with 
Coomassie blue as an internal, total protein loading control. Proteins from the remaining part 
of the gel were transferred to nitrocellulose membrane and developed with the appropriate 
antibody. Quantification of protein levels was performed by normalising densitometry 
measurements of antibody reactive bends to densitometry measurements of Coomassie 
stained gel. Image created with BioRender.com. B) Representative western blots showing 
lamin A/C protein levels in the heart, spinal cord, brain, liver and muscle tissue from SMA 
mice (n=5) and healthy controls (n = 5), and in fibroblast cells from SMA patients (n = 3) and 
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age matched male healthy controls (n = 3). Fibroblast cells are listed in this order: 1. 
GM00498, 2. GM05659, 3. GM00302, 4. GM03813, 5. GM09677, 6. GM00232. The 
uncropped blots and total protein loading controls can be found in the Supplementary File 
(S3). C) Quantification of lamin A/C levels in tissues from SMA mice and in patient 
fibroblast cells. In the liver extract, the lower band was presumed to be lamin C, and the 
upper two bands were presumed to be lamin A isoforms and were consequently measured 
together to give a single value. The graph is presented as average protein levels in SMA 
tissues (expressed relative to the control), with error bars showing standard deviation from 
the mean. The dashed line represents protein levels across healthy control tissues. D) 
Representative immunohistochemistry images showing lamin A/C staining in the heart from 
SMA mouse (P8) and healthy age-matched control. Scale bar = 50 μm. Increased lamin A/C 
staining can be observed in the ventricle wall from SMA mouse, with few lamin A/C positive 
cells found in the ventricle lumen. E) Densitometry measurements of lamin A/C levels in the 
ventricle wall are presented as mean optical density, with error bars showing standard 
deviation from the mean. F) Lamin A transcript levels in the heart from SMA mice (n = 4) 
and healthy controls (n = 4) and in fibroblast cells from SMA patients (n = 3) and healthy 
controls (n = 3). Expression levels of lamin A were normalized to the geometric mean of 
POLR2J and TBP. The graphs are presented as mean expression, with error bars showing 
standard deviation from the mean. CTR- control; ns—not significant; * p < 0.05; ** p < 0.01; 
*** p < 0.001.
Figure 3. UBA1 and lamin A/C are mechanistically linked 
Western blots showing lamin A/C, UBA1 and SMN protein levels in the A) heart, muscle, 
liver, brain and spinal cord tissue from healthy control mice (n=2) and in fibroblast cells from 
healthy individuals (n=2), in B) UBA1 KD and control HEK cells (n = 3) and in C) LMNA 
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KO and wild type MEFs (n = 3). The uncropped blots and loading controls can be found in 
the Supplementary File (S5 and S6). Graphs are presented as average protein levels 
(expressed relative to the control), with error bars showing standard deviation from the mean. 
The dashed line represents protein levels in control cells. H-heart; M-muscle; L-liver; B-
brain; SP-spinal cord; FC-fibroblast cells; ns—not significant; *p < 0.05; ** p < 0.01; *** p 
< 0.001. 
Figure 4. Lamin A/C interacts with β-catenin in mouse heart
A) Representative immunocytochemistry images showing lamin A and UBA1 staining in 
control and SMA patient fibroblast cells. Arrows in the lower magnification images indicate 
cells with the most obvious UBA1 staining at the nuclear periphery. Scale bar = 25 μm. Scale 
bar = 10 μm (control) and 7.5 μm (SMA) in higher magnification images. B) Western blots 
showing lamin A/C, UBA1 and β-catenin expression in the heart tissue from control and 
SMA mice after immunoprecipitation with anti-lamin A/C antibody. Beads alone control 
lanes refer to heart extracts incubated with Dynabeads without the antibody, and represent 
negative control. #β-catenin band was detected in the eluate from lamin A/C pulldown in both 
control and SMA samples, but was not observed in the eluate from the beads alone control. 
Figure 5. Model of how lamin A/C dysregulation, in combination with other molecular 
changes, may contribute to cardiac pathology in SMA. A model is proposed in which 
lamin A/C up-regulation, in combination with other molecular changes that occur in SMA, 
may lead to cardiac fibrosis and impaired cardiac function. Thinner ventricle walls and 
dilated ventricles in SMA heart are clinical features of dilated cardiomyopathy. Image created 
with BioRender.com.
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Abbreviations
SMA- spinal muscular atrophy
SMN- survival of motor neuron
SMN1- survival of motor neuron 1, telomeric
SMN2- survival of motor neuron 2, centromeric
LMNA- lamin A/C
ECG- electrocardiogram
iTRAQ- isobaric tags for relative and absolute quantitation
DAVID- database for annotation, visualization and integrated discovery
STRING 10- search tool for the retrieval of interacting genes/proteins
GO- gene ontology
P8-postnatal day 8
RT-qPCR- reverse transcription- quantitative polymerase chain reaction
Ct- cycle threshold
HEK cells - human embryonic kidney cells
MEFs- mouse embryonic fibroblasts
UBA1- ubiquitin like modifier activating enzyme 1
GARS1- glycyl-tRNA synthetase 1
SMAX2- spinal muscular atrophy, x-linked 2
MSCs- mesenchymal stem cells
SUN2- SUN domain-containing protein 2
SUN2- Sad1 and UNC84 domain containing 2
Cdc5l- cell division cycle 5-like protein
RPLC- reverse-phase liquid chromatography
LC-ESI-MS/MS - liquid chromatography-tandem mass spectrometry
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OD- optical density
FA- formic acid
DDA- data-dependent acquisition
CE- collision energy
FDR- false discovery rate
PSPEP- Proteomics System Performance Evaluation Pipeline
DMEM- Dulbecco's Modified Eagle Medium
FBS- fetal bovine serum
MEM-NEAA- non-essential amino acids
PEN-STREP- penicillin-streptomycin
KD- knockdown
KO- knockout
SDS-PAGE- sodium dodecyl sulfate- polyacrylamide gel electrophoresis
BSA- bovine serum albumin
PBS- phosphate-buffered saline
NTC- no-template control
POLR2J- RNA polymerase II subunit J
TBP- TATA-Box binding protein
OCT- optimum cutting temperature compound
DAPI- 4’,6-diamidino-2-phenylindole
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